MedTrace Logo

Liposomal Irinotecan and Capecitabine Plus Bevacizumab as Second-line Therapy in Metastatic Colorectal Cancer

NCT06192680 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 63

Last updated 2024-01-18

No results posted yet for this study

Summary

This multicenter, single-arm trial will explore the efficacy and safety of liposomal irinotecan and capecitabine plus bevacizumab as second-line therapy in metastatic colorectal cancer.

Conditions

Interventions

DRUG

Liposomal irinotecan

70 mg/m² IV

DRUG

Capecitabine

1000 mg/m² PO BID

DRUG

Bevacizumab

5mg/kg IV

Sponsors & Collaborators

  • Harbin Medical University

    lead OTHER

Principal Investigators

  • Yanqiao Zhang, Professor · The Second Affiliated Hospital of Harbin Medical University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-01
Primary Completion
2025-11-30
Completion
2026-09-30

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06192680 on ClinicalTrials.gov